Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Acumen Pharmaceuticals, Inc. (ABOS) had Normalized Income after Taxes of $-121.33M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-121.33M |
|
-- |
|
-- |
|
$123.83M |
|
$-123.83M |
|
$2.50M |
|
$-121.33M |
|
$-121.33M |
|
$-121.33M |
|
$-121.33M |
|
$-121.33M |
|
|
Normalized Income after Taxes |
$-121.33M |
$-123.83M |
|
$-124.46M |
|
60.56M |
|
60.56M |
|
$-2.00 |
|
$-2.00 |
|
| Balance Sheet Financials | |
$122.25M |
|
-- |
|
$0.58M |
|
$122.83M |
|
$30.01M |
|
$22.40M |
|
$22.40M |
|
$52.40M |
|
$70.43M |
|
$70.43M |
|
$70.43M |
|
60.58M |
|
| Cash Flow Statement Financials | |
$-115.54M |
|
$133.93M |
|
$-0.03M |
|
$35.86M |
|
$54.22M |
|
$18.36M |
|
$9.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.07 |
|
-- |
|
-- |
|
0.24 |
|
0.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-115.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-172.28% |
|
-172.28% |
|
-98.78% |
|
-130.71% |
|
$1.16 |
|
$-1.91 |
|
$-1.91 |
|